Le Qin

Title: Le Qin - Innovator in Chimeric Antigen Receptor Technology

Introduction

Le Qin is a prominent inventor based in Guangdong, China. He has made significant contributions to the field of biomedicine, particularly in the development of chimeric antigen receptors (CARs) for cancer treatment. His innovative work has the potential to improve patient outcomes in oncology.

Latest Patents

Le Qin holds a patent for a scFv amino acid sequence, which is capable of recognizing the CD19 antigen. This patent also includes a chimeric antigen receptor that incorporates this sequence, along with its applications in the manufacture of medicaments for treating tumors. The chimeric antigen receptor developed by Le Qin features at least one extracellular domain, an optional transmembrane domain, and at least one intracellular costimulatory signaling domain. This innovative receptor has been humanized, leading to longer survival periods in vivo and extended complete remission periods for patients.

Career Highlights

Le Qin is associated with Guangdong Zhaotai Invivo Biomedicine Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to improving therapeutic strategies for cancer treatment through innovative biotechnological solutions.

Collaborations

Le Qin collaborates with notable colleagues, including Peng Li and Ruocong Zhao, who contribute to his research endeavors and help drive forward the mission of their organization.

Conclusion

Le Qin's contributions to the field of biomedicine, particularly through his patented innovations in chimeric antigen receptor technology, highlight his role as a key inventor in the fight against cancer. His work promises to enhance treatment options and improve the quality of life for patients battling tumors.